News

Roche has received this license pursuant to an agreement between Genentech and Roche under which Genentech granted Roche an option to obtain a license to commercialize certain Genentech

TQ-1015 is being developed using Securel, TheraQuest’s abuse deterrent technology. TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain. Najib Babul, CEO of

Watson is seeking marketing approval of the Trelstar formulation for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on its application in

Under the terms of this agreement, researchers from the laboratory of Fatiha Nothias will collaborate with BioForce to develop technologies, protocols, and products related to neural cell-based assays.

The FDA has established a December 30, 2008 prescription drug user fee act target action date. Amag is seeking marketing approval for ferumoxytol for the treatment of iron

The agreement reportedly allows Zoll to manufacture the Zoll E Series defibrillators with the Rainbow Set technology that non-invasively and continuously measures carbon monoxide and methemoglobin levels in

DermaVir Patch, the company’s nanomedicine candidate for treatment-naive HIV-infected individuals, is designed to amplify de novo HIV-specific memory T-cell responses of HIV-infected individuals and improve the ability of

Pursuant to the terms of the agreement, Sigma-Aldrich will now be the exclusive supplier of AlphaGenix-developed antibodies and research tools for the fields of regenerative medicine and stem

This expanded feasibility agreement builds upon the successful completion of a previous research study between the parties. Scope and terms of the agreement were not disclosed. Ray Salemme,